Russian Study of the Effect of Continuous Positive Airway Pressure (CPAP) in Hypertension
Primary Purpose
Obstructive Sleep Apnea Syndrome, Hypertension
Status
Completed
Phase
Phase 3
Locations
Russian Federation
Study Type
Interventional
Intervention
cPAP
Sponsored by
About this trial
This is an interventional treatment trial for Obstructive Sleep Apnea Syndrome focused on measuring obstructive sleep apnea, obstructive sleep apnea syndrome, hypertension, systemic hypertension, ambulatory blood pressure monitoring
Eligibility Criteria
Inclusion Criteria:
- male/female over than 18 years old
- patient with an obstructive sleep apnea (apnea-hypopnea index > or equal to 15)
- patient with weak or moderate hypertension (140 <= SBP < 180 mmHg and 90 <= DBP < 110 mmHg)
- negative pregnancy test
- ambulatory patient
- patient who have signed the informed consent form
Exclusion Criteria:
- pregnant or nursing woman
- woman who refuses to use contraceptive method
- acute hepatic failure, biliary cirrhosis, cholestasis
- clearance of Cockcroft < 30 ml/min/1.73m2
- kaliemia >= 5.5 mmol/l
- acute hypertension (SBP>= 180 mmHg and/or DBP >= 110 mmHg)
- acute daytime sleepiness (Epworth rating scale > 15)
- patient with a profession that is inconsistent with the continuous positive airway pressure (CPAP) treatment
- known cardiovascular pathologies
- contraindication to CPAP
- allergy to valsartan and/or amlodipine
- patient treated with lithium
- patient on tutelle or curatelle
- patient kept in detention, major protected by the law, hospitalized person patient currently participating in another clinical trial
Sites / Locations
- Russian Cardiologe Research and Production Complex
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Sham Comparator
Arm Label
1
2
Arm Description
Outcomes
Primary Outcome Measures
Ambulatory blood pressure monitoring over 24 hours, at inclusion visit (day=0), before cPAP (3-9 weeks) and after 3 weeks of cPAP.
Secondary Outcome Measures
Full Information
NCT ID
NCT00801671
First Posted
June 19, 2008
Last Updated
June 15, 2011
Sponsor
Russian Cardiology Research and Production Center
1. Study Identification
Unique Protocol Identification Number
NCT00801671
Brief Title
Russian Study of the Effect of Continuous Positive Airway Pressure (CPAP) in Hypertension
Official Title
Study of Independent Role of Continuous Positive Airway Pressure Therapy on Systemic Arterial Pressure in Patients With Sleep Apnea Syndrome and Arterial Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
June 2011
Overall Recruitment Status
Completed
Study Start Date
September 2008 (undefined)
Primary Completion Date
June 2011 (Actual)
Study Completion Date
June 2011 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Russian Cardiology Research and Production Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine whether CPAP is effective in the treatment of systemic hypertension.
Detailed Description
It is now well known that cardiovascular risks are increased in patients with obstructive sleep apnea syndrome (OSAS). Also a link has already been demonstrated between OSAS and hypertension.
Nowadays, the most efficient treatment of the OSAS is the continuous Positive Airway Pressure (cPAP). Several studies have also shown that cPAP could reduce arterial blood pressure in OSAS patients. But level of blood pressure (BP), drug treatment were not equal between groups and it's difficult to single out independent role of cPAP.
Our study has the objective to compare the effects of cPAP on hypertension in OSAS patients. After 3-9 weeks of antihypertensive treatment (valsartan and amlodipine) those one who reached target level of BP will be randomized either in the group "treatment by cPAP" or in the group "treatment by cham-cPAP" for 3 weeks and then we'll perform cross-over.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obstructive Sleep Apnea Syndrome, Hypertension
Keywords
obstructive sleep apnea, obstructive sleep apnea syndrome, hypertension, systemic hypertension, ambulatory blood pressure monitoring
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Active Comparator
Arm Title
2
Arm Type
Sham Comparator
Intervention Type
Procedure
Intervention Name(s)
cPAP
Intervention Description
After reaching target level of BP patients will be randomized in active group (cPAP) and control group (sham-cPAP)
Primary Outcome Measure Information:
Title
Ambulatory blood pressure monitoring over 24 hours, at inclusion visit (day=0), before cPAP (3-9 weeks) and after 3 weeks of cPAP.
Time Frame
24 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
male/female over than 18 years old
patient with an obstructive sleep apnea (apnea-hypopnea index > or equal to 15)
patient with weak or moderate hypertension (140 <= SBP < 180 mmHg and 90 <= DBP < 110 mmHg)
negative pregnancy test
ambulatory patient
patient who have signed the informed consent form
Exclusion Criteria:
pregnant or nursing woman
woman who refuses to use contraceptive method
acute hepatic failure, biliary cirrhosis, cholestasis
clearance of Cockcroft < 30 ml/min/1.73m2
kaliemia >= 5.5 mmol/l
acute hypertension (SBP>= 180 mmHg and/or DBP >= 110 mmHg)
acute daytime sleepiness (Epworth rating scale > 15)
patient with a profession that is inconsistent with the continuous positive airway pressure (CPAP) treatment
known cardiovascular pathologies
contraindication to CPAP
allergy to valsartan and/or amlodipine
patient treated with lithium
patient on tutelle or curatelle
patient kept in detention, major protected by the law, hospitalized person patient currently participating in another clinical trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexandr Yu Litvin, MD
Organizational Affiliation
Russian Cardiology Research and Production Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Russian Cardiologe Research and Production Complex
City
Moscow
ZIP/Postal Code
121552
Country
Russian Federation
12. IPD Sharing Statement
Citations:
PubMed Identifier
23690688
Citation
Litvin AY, Sukmarova ZN, Elfimova EM, Aksenova AV, Galitsin PV, Rogoza AN, Chazova IE. Effects of CPAP on "vascular" risk factors in patients with obstructive sleep apnea and arterial hypertension. Vasc Health Risk Manag. 2013;9:229-35. doi: 10.2147/VHRM.S40231. Epub 2013 May 10.
Results Reference
derived
Learn more about this trial
Russian Study of the Effect of Continuous Positive Airway Pressure (CPAP) in Hypertension
We'll reach out to this number within 24 hrs